p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition  by Ji, Zhenyu et al.
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Zhenyu Ji1,2, Ching Ni Njauw2, Michael Taylor2, Victor Neel2, Keith T. Flaherty3 and Hensin Tsao1,2,3
Oncogenesis reflects an orchestrated interaction between misguided growth signals. Although much effort has
been launched to pharmacologically disable activated oncogenes, one sidelined approach is the restoration of
tumor suppressive signals. As TP53 is often structurally preserved, but functionally crippled, by CDKN2A/ARF
loss in melanoma, rescue of p53 function represents an attractive point of vulnerability in melanoma. In this
study, we showed that both p53 protein and activity levels in melanoma cells were strongly induced by nutlin-3,
a canonical HDM2 antagonist. Among a test panel of 51 cell lines, there was a marked reduction in melanoma
viability that was directly linked to TP53 status. Moreover, we also found that the melanoma growth suppression
mediated by mitogen-activated protein kinase/extracellular signal-regulated kinase inhibition was potentiated
by HDM2 antagonism. These results provide fundamental insights into the intact p53 circuitry, which can be
restored through small molecule inhibitors and potentially deployed for therapeutic gain.
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INTRODUCTION
Melanoma is one of the most aggressive cancers accounting
for 80% of skin cancer-related deaths (Miller and Mihm,
2006). With advances in cancer genetics and genomics, a
host of oncogenic loci have been recently uncovered in
melanoma, thereby opening new therapeutic avenues. In
the 1990s, loss of CDKN2A was recognized as a crucial
molecular gatekeeper in the pathogenesis of melanoma
(Hussussian et al., 1994; Kamb et al., 1994); an alternative
transcript of CDKN2A (p14ARF) was subsequently found to
stabilize p53 by antagonizing HDM2 (Kamijo et al., 1997;
Pomerantz et al., 1998; Zhang et al., 1998). Thus, p14ARF
loss accelerates the HDM2-mediated abrogation of p53
function in melanoma (Yang et al., 2005).
Systematic genomic resequencing of RAS pathway genes
led to the discovery of recurrent mutations at interactive loci,
including NRAS (Albino et al., 1984; Padua et al., 1984;
van‘t Veer et al., 1989), BRAF (Davies et al., 2002), and PTEN
(Tsao et al., 2004). The most prominent of these, BRAF, has
been reported to be mutated at T1799 in about half of the
common types of melanomas (Hocker and Tsao, 2007). This
V600E change leads to a constitutive activation of the
mitogen-activated protein kinase (MAPK) signaling cascade.
Given its prevalence, BRAFV600E became an attractive, broadly
applicable molecular target in melanoma drug design. How-
ever, despite the recent successes with PLX4032, a BRAFV600E-
specific compound in early trials, disease progression ulti-
mately follows initial response to therapy, although over a
variable period of treatment (Chapman et al., 2011). Therefore,
it appears that single target therapy does not produce sufficient
durable responses for more than a minority of patients, and
additional strategies are critically required (Ji et al., 2010).
Although most successes in molecular therapies have been
attributed to the pharmacological attenuation of oncogenic
signals, another theoretical tactic is the restoration of tumor
suppressor function, which remains a complementary yet
largely untapped approach. Although p53 is one of the most
frequently mutated tumor suppressor genes in cancer, it is
mutated in only about 13% of uncultured melanoma speci-
mens (Castresana et al., 1993; Albino et al., 1994; Hocker
and Tsao, 2007). The absence of p53 mutations in melanoma
has been attributed to the epistatic loss of ARF (Hocker and
Tsao, 2007) or amplification of HDM2 (Muthusamy et al.,
2006), both of which lead to a functionally debilitating
interaction between HDM2 and p53. Mechanistically, how-
ever, the lack of crippling p53 mutations does suggest that
small-molecule rescue strategies may be effective in mela-
noma. Indeed, there has been preliminary evidence that p53
activation is involved in apoptosis induction by GSK3b
inhibitors or BH3 mimetics in melanoma cells (Verhaegen
et al., 2006; Smalley et al., 2007).
Recently, small molecular inhibitors that disrupt the
negative interaction between HDM2 and p53 were isolated
and were shown to effectively activate the p53 pathway in
cancer cells, thereby inducing cell cycle arrest and apoptosis
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(Vassilev et al., 2004). The nutlins are cis-imidazoline-
derived compounds that potently and specifically inhibit
the HDM2-p53 interaction; one of these, nutlin-3, is currently
being evaluated for its therapeutic action in human cancer
(Shangary and Wang, 2009). To date, the thrust of HDM2
antagonist development has focused on hematological
malignancies, in which p53 is also largely intact such as in
melanomas (Secchiero et al., 2008).
Given the context of vulnerability for melanoma, we set
out to validate HDM2 antagonism as a means of restoring
p53 activity and suppressing melanoma growth. Our early
results support the potential utility of this strategy and
demonstrate the effective restoration of a tumor suppressive
function, both in single and dual target formulations.
RESULTS
p53 rescue is genetically tractable in melanoma
To examine the genetic context of nutlin sensitivity, we
sequenced TP53 (exons 4–10) in a set of 51 melanoma lines
targeted for nutlin-3 treatment (Table 1). Approximately 71%
(36 of 51) of the lines were wild type (WT) for TP53. Using
single-nucleotide polymorphism/comparative genomic hybri-
dization, we found that 25 of 36 TP53WT lines (69%)
exhibited concurrent copy number (CN) loss of the CDKN2A
region, with 11 of the 25 CN losses being high CN losses
suggestive of homozygous deletions. In contrast, only 5 of 15
TP53MUT lines (33%) exhibited evidence of CN loss at
CDKN2A (69% vs. 33%, P¼0.028). This is consistent with
the idea that preferential loss of CDKN2A in TP53 WT cells
may in fact be driven, in part, by p14ARF inactivation and
heightened HDM2 activity (Zhang et al., 1998). We thus
confirmed the relatively low prevalence of mutated TP53 in
melanomas and pursued HDM2 antagonism as a viable
strategy to restore p53 function in these cells.
HDM2 antagonism with nutlin-3 restores p53 function and
reduces cellular viability
As shown in Figure 1a, exposure to nutlin-3, the prototypic
HDM2 antagonist, led to increased levels of intracellular p53.
However, p21 (a p53 target) was only upregulated in TP53WT
melanoma cells, but not in TP53MUT cells. Similar results
were obtained using a luciferase reporter under the control of
a p53 promoter (Figure 1b). Thus, both p53 protein and
activity levels could be rescued in TP53WT melanoma cells
with HDM2 antagonism.
We next subjected 51 genetically characterized mela-
noma lines to escalating concentrations of nutlin-3 and
observed a dose-dependent decrease in cell viability. The
median survival fractions (fs) of all 51 lines are shown in
Figure 1c (0.82, 0.67, and 0.60 for 5 mM, 10 mM, and 20mM,
respectively), whereas the GI50 values are ranked and plotted
in Figure 1d. When these effects were examined relative to
TP53 status, nutlin-3 (10 mM) was clearly less effective in
TP53MUT lines compared with TP53WT (Figure 1e; median
fs¼0.88 vs. 0.63; Po0.001). Taken together, we present
evidence that nutlin-3 can suppress viability in vitro and that
drug response is under the genetic influence of TP53.
Table 1. TP53, CDKN2A, and BRAF status on test lines
Sample TP53 (exons 4–10) CDKN2A BRAF
WM1552C R248Q/+ Homozygous copy loss V600E
MGH-BA-1 G245D Homozygous copy loss V600E
WM451Lu Y220C CN loss V600E
WM1158 P98A/+ CN loss V600E
NAE F270I CN loss V600E
WM164 Y220C V600E
A2058 V274F V600E
RPMI-7951 S166X V600E
K1 R273H V600E
SK Mel 37 R175H V600E
SK Mel 28 L145R V600E
HMCB H193R WT
CHL-1 H193R WT
LH G244R WT
Sk Mel 39 F113S V600E
MM455 WT Homozygous copy loss V600E
MM608 WT Homozygous copy loss V600E
WM115 WT Homozygous copy loss V600E
A373-C6 WT Homozygous copy loss V600E
A375 WT Homozygous copy loss V600E
Malme3M WT Homozygous copy loss V600E
Quinn WT Homozygous copy loss V600E
RU WT Homozygous copy loss V600E
UACC903 WT Homozygous copy loss V600E
WM239A WT Homozygous copy loss V600D
WM266-4 WT Homozygous copy loss V600E/D
Bower WT CN loss V600E
Colo783 WT CN loss V600E
G-361 WT CN loss V600E
MGH-MC-1 WT CN loss V600E
MEL H0 WT CN loss V600E
RVH-421 WT CN loss V600E
MGH-ST-1 WT CN loss V600E
WM902B WT CN loss V600E
C32 WT CN loss V600E
COLO679 WT CN loss V600E
COLO853 WT CN loss V600E
HS940T WT CN loss WT
K4 WT CN loss V600E
Mel-Juso WT CN loss WT
WM278 WT V600E
MGH-CH-1 WT V600E
SK Mel 63 WT WT
HS597T WT WT
HS688T WT WT
Hs839T WT WT
HS944T WT WT
K2 WT V600E
K23 WT WT
WM1205 WT V600E
WM793 WT V600E
Abbreviations: CN, copy number; WT, wild type.
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However, as the BRAFMUT/TP53WT dual genotype comprises
the largest fraction of cases (27 of 51, 53%, Table 1), we next
sought to determine whether nutlin-3’s effects could be
enhanced by U0126, a MAPK/extracellular signal-regulated
kinase (MEK) inhibitor previously shown to selectively
suppress proliferation and to induce apoptosis in BRAF-
mutated lines (Solit et al., 2006).
Nutlin-3 and MEK inhibitor U0126 exhibit additive effects
To test the possibility that MEK inhibition and HDM2
antagonism could synergize each other’s growth suppressive
effects, we exposed all 51 melanoma lines to escalating doses
of MEK inhibitor U0126, both singly and in combination with
nutlin-3 (raw data available as Supplementary Table S1
online). As shown in Figure 2a, the median fs values were
0.76, 0.74, and 0.78 for 3, 10, and 30 mM of U0126. As
expected (Solit et al., 2006), BRAF-mutated lines appeared to
be more sensitive to U0126 compared with BRAF-WT lines
(Supplementary Figure S1 online; median fs¼1.0 vs. 0.79,
Po0.001).
We next sought evidence for synergy between nutlin-3
and U0126. On exposure to concomitant nutlin-3 and
U0126, there was appropriate stabilization of p53 levels
and induction of p21, along with concurrent suppression of
pERK (Figure 2b). In Figure 2c–e, the nutlin-3 and U0126
dose–effect curves (left panel) and combination isobolograms
(right panel; nine dose combinations) are shown for three
illustrative melanoma lines. WM902B (Figure 2c) was neither
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Figure 1. HDM2 antagonism restores p53 levels and activity. (a) Nutlin-3 exposure (10 mM for 24 hours) increases intracellular p53 levels; however,
upregulation of p21, a direct p53 target, occurs selectively in TP53WT, but not in TP53MUT, cell lines. (b) With a p53-promoter luciferase reporter, activity is also
selectively induced in TP53 wild-type lines by nutlin-3 treatment (10 mM for 24 hours). (c) Melanoma cell lines (N¼ 51) exhibited varying sensitivities to
increasing concentrations of nutlin-3 (dotted lines represent the 75th and 25th percentile boundaries as defined at various doses (triangle for 75th percentile and
‘‘x’’ for 25th percentile); the solid line shows the median fractional survival (fs)). (d) Calculated GI50 values for cell lines; GI50 values below and above
the minimum and maximum nutlin-3 concentrations, respectively, were delimited by dose. Small bars underneath the x axis indicate p53 mutant lines.
(e) In aggregate, TP53MUT lines were more resistant to nutlin-3 (10 mM) than were TP53WT lines. For the survival assays, cells were exposed to the indicated doses
of nutlin-3 for 48 hours and checked for viability with the AlamarBlue assay. D, DMSO; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; N, nutlin-3.
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sensitive to U0126 nor to nutlin-3 alone, but was strongly
inhibited when the two agents were combined (combination
index (CI)o0.1). For cell lines such as C32 (Figure 2d), there
was an enhancement of the blunted U0126 response with the
addition of nutlin-3 (CI o0.1). In contrast, lines such as
A373-C6 (Figure 2e) showed moderate sensitivity to both
U0126 and nutlin-3 alone, and thus concurrent administra-
tion did not result in as vigorous a synergistic effect. We
calculated the CIs for all nine dose combinations in 41 cell
lines and mapped them to a cell linedose combination
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Figure 2. U0126 and combinatorial responses. (a) Sensitivity of 51 cell lines to escalating doses of U0126 (dotted lines represent the 75th and 25th percentile
boundaries as defined at various doses (triangle for 75th percentile and ‘‘x’’ for 25th percentile); the solid line shows the median fractional survival (fs)).
(b) Demonstration of concurrent pERK inhibition by U0126 and p53 deployment by nutlin-3. (c–e) Three examples of U0126þ nutlin-3 synergy. The left panels
show dose–response curves for nutlin-3 (blue circle), U0126 (red square), and combination (green triangles), whereas the right panels show the combination
isobolograms. In c and d, there was greater suppression with the combination than with either agent alone. Accordingly, the isobolograms indicated strong
synergy. In e, both U0126 and nutlin-3 showed significant effects; thus, the combination indices (CIs), which were still in the synergistic range, were less
pronounced. In f, a heat map of the cell lines, grouped by TP53 status, and the various dose combinations (nutlin-3¼N, U0126¼U, all concentrations mM,
5N¼5 mM nutlin-3 and 3U¼ 3 mM U0126, etc.; 1¼5Nþ 3U, 2¼5Nþ 10U, 3¼ 5Nþ30U, 4¼ 10Nþ 3U, 5¼10Nþ 10U, 6¼ 10Nþ30U, 7¼ 20Nþ 3U,
8¼ 20Nþ10U, 9¼ 20Nþ 30U) are shown. Red color indicates a lack of synergy (CI41), whereas bright green indicates strong synergy (CIo0.1);
the color inflection point is at CI¼0.5. Cell lines that show synergy across all dose combinations are represented as a green column. D, DMSO;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; N, nutlin-3; U, U0126.
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‘‘heat map’’ matrix (Figure 2f). There were clearly pockets of
synergy (green boxes; scale: CIo0.1, bright green—CI¼ 1.0,
red) throughout the various lines and fluctuations within dose
combinations; this did not appear to correlate with the TP53
status. It is notable that some cell lines showed a potentiating
effect across all dose combinations, whereas others exhibited
effects that were quite focal. This is to be expected, as
synergy becomes more difficult to demonstrate in the context
of high sensitivity. Using the classification of Chou (2010), we
found evidence for ‘‘Very Strong Synergism’’ in 8 lines (20%),
‘‘Strong Synergism’’ in 8 lines (20%), ‘‘Synergism’’ in 6 lines
(15%), ‘‘Moderate Synergism’’ in 2 lines (5%), ‘‘Near
Additive Effects’’ in 1 line (2%), and ‘‘Antagonism’’ in 16
lines (38%). In other words, 24/41 (60%) of the melanomas
showed some evidence of synergy between U0126 and
nutlin-3 (Figure 2f).
In addition, one of the hypotheses that triggered this line of
investigation was that the combination of anti-MAPK and
anti-HDM2 treatments should correlate with molecular status
(Figure 3). To substantiate the genotype/phenotype relation-
ship, we examined median fs as a function of BRAF and TP53
status. The observed genetic effects corroborated the initial
hypothesis, as melanoma lines with the dual BRAFMUT/
TP53WT genotype appeared to be the most sensitive subgroup
when cells were exposed to combination nutlin-3 and
U0126. Taken together, these experiments verify the added
utility of an anti-MEKþ anti-HDM2 combination, especially
under certain genetic contexts.
MEK inhibition and HDM2 antagonism result in apoptosis
and cell cycle arrest via a p53-dependent mechanism
Having demonstrated the growth suppressive effects of nutlin-
3 singly and in combination with U0126, we next set out to
determine whether the inhibition is due to cell cycle arrest or
apoptosis, or a combination of both. We performed the
experiments with two MEK inhibitors, U0126 (the research
tool compound) and AZD6244 (a clinically tested drug).
Figure 4 illustrates the cell cycle profiles (left panel) and
caspase 3/7 activities (right panel) for four melanoma lines.
Nutlin-3 (8 mM) induced a G2 arrest after 48 hours, whereas
U0126 (2 mM) and AZD6244 (2 mM) more consistently
produced a G1 arrest; we have occasionally observed some
G2 effects at higher U0126 concentrations (Supplementary
Figure S2 online). When nutlin-3 was combined with either
MEK inhibitor (dosage indicated), there was evidence of
enhanced apoptosis as determined by both sub-G1 fractiona-
tion and by a caspase 3/7 fluorometric assay (Figure 4).
Strikingly, with AZD6244 (2 mM), the addition of nutlin-3
(8 mM) consistently led to an B30% increase in the sub-G1
fraction across all lines, a finding that was further corrobo-
rated by the caspase 3/7 assays (Figure 4).
To more formally link p53 function to the apoptotic
response observed with these compounds, we stably ex-
pressed small hairpin RNA (shRNA) against p53 in A375
melanoma cells. As shown in Figure 5a, the A375sh-p53 cells
neither deployed p53 nor induced its targets HDM2 and p21
in response to nutlin-3. However, upon exposure of control
A375sh-GFP cells to U0126, nutlin-3, and AZD6244 (Figure
5b), singly or in combination, there were marked increases in
the sub-G1 fraction, which were all effectively abrogated in
the A375sh-p53 cells. Taken together, p53 appears to be
essential in mediating the apoptotic responses to nutlin-3,
whether the drug is used alone or in conjunction with MEK
inhibitors.
DISCUSSION
It has been held that melanomas infrequently exhibit TP53
mutations given the high frequency of functional compromise
through p14ARF loss (Hocker et al., 2008); we now provide
supportive evidence of this supposition by demonstrating a
higher proportion of CDKN2A CN loss among TP53WT lines.
Furthermore, we hypothesize that p53 rescue may be an
effective molecular strategy in melanoma therapeutics and,
through this study, establish early preclinical data outlining
this approach. There are several notable points that emerged
from these results.
In a significant fraction of melanomas, both p53 activity
and growth suppression can be effectively induced with
nutlin-3; moreover, sensitivity to the HDM2 antagonist is
dependent on available p53 and is strongly correlated with
TP53 status. We selected nutlin-3 as it represents the first of
a class of small molecules that have been developed to
disrupt HDM2-p53 binding and reactivate p53 proteins
(Vassilev et al., 2004). Tseng et al. (2010) recently reported
that nutlin-3 had minimal apoptotic effects on a panel of
melanoma lines, although it potentiated apoptosis induced
by TRAIL and blunted apoptosis in response to docetaxel. The
precise mechanisms that produce the mixed response are not
known. There is clearly a broad range of innate sensitivities
to nutlin-3 (Figure 1), and the relationship to TP53 is a clear
trend but not an absolute. Thus, other genetic or epigenetic
elements in the cell most likely modulate nutlin-3 response.
In our experiments, we prescreened cells for normal p53 and
moderate nutlin-3 sensitivity before our apoptotic analysis;
this may have enriched for cells that are inherently more
responsive and partly explains the difference between our
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findings and those of Tseng et al. (2010). Technical
differences may also have a role. Nevertheless, these
experimental results, which need independent replication,
strongly suggest that some melanoma cells undergo apoptosis
in response to HDM2 antagonism and that p53 is required for
this effect. Nutlin-3 has also shown activity in the treatment
of mouse xenograft models of prostate cancer, osteosarcoma,
and lymphoma (Vassilev et al., 2004; Tovar et al., 2006;
Sarek et al., 2007). More recently, R7112, a family member of
nutlin-3, has been introduced into human trials as mono-
therapy for advanced solid tumors (Roche, 2009a) and
hematological malignancies (Roche, 2009b). Our study
would support the eventual deployment of R7112 or a
similar HDM2 antagonist in melanoma trials.
In addition to its suppressive effects alone, nutlin-3 also
synergized with MEK inhibition in a substantial proportion of
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Figure 4. Physiological responses to nutlin-3 and mitogen-activated protein kinase/extracellular signal-regulated kinase inhibition. Four p53 wild-type
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melanomas. MEK inhibition is currently a viable clinical
option in melanoma. We initially selected U0126 in the
screen, given its ready access and its well-characterized
history, as a tool compound for MAPK pathway inhibition.
When CIs were calculated for nutlin-3/U0126 combinations,
it was clear that there were unique pockets of synergistic
vulnerability, which might have been overlooked if a single
dose mix had been selected. Moreover, as predicted by
mechanism and supported by our observations, the combina-
tion of U0126þnutlin-3 was most effective in cells with
BRAF mutations and WT TP53, thus providing an early step
toward deeper personalization with multiple molecular
indices. Although the genetic governance is far from
absolute, in aggregate, the addition of nutlin-3 to U0126
reduced the mean fs by about 0.20. Kojima et al. (2007) have
also reported the potentiation of PD98059-mediated MEK
inhibition by nutlin-3 in two acute myelogenous leukemia
lines.
One unexpected but clinically exciting finding is that
nutlin-3 appears to enhance apoptotic killing by AZD6244, a
highly selective MEK1/2 inhibitor that showed modest
success in clinical trials (Adjei et al., 2008). A part of its
limiting effects on melanoma may be because of the
preferential cytostasis rather than apoptosis induced by
AZD6244 (Haass et al., 2008). Although the underlying
mechanisms related to HDM2 antagonism and p53 recruit-
ment is far from elucidated, our studies raise the possibility
that restoration of p53 may in fact contribute to a cytotoxic
‘‘switch’’, which allows for more efficient eradication of
melanoma cells in the clinic.
There are several limitations to this study. First, the advent
of highly selective BRAF inhibitors brings forth the untested
possibility that HDM2 antagonism could have similar
additive effects with drugs such as vemurafenib. Our studies
do not directly address therapeutic interactions between
highly selective BRAF inhibitorss and HDM2 antagonists,
although there is no a prior reason to think that a combination
of HDM2 antagonists with highly selective BRAF inhibitorss
would lead to markedly different results. Second, in the
absence of bona fide clinical trial data, the cumulative
toxicity of MAPK inhibition and HDM2 antagonism cannot
be appropriately judged. As in vitro tools, U0126, AZD6244,
and nutlin-3 have been widely used in laboratory investiga-
tion; however, none of the compounds are currently being
pursued as viable clinical drugs. Nevertheless, a host of BRAF
and MEK inhibitors are in clinical trials, as is the HDM2
antagonist R7112; thus, human studies that involve combina-
tions of these classes of agents may be possible in the near
future.
In summary, we set out to show that p53 rescue may be a
new and important therapeutic approach in melanoma, given
the known genetic structure of this cancer. We provide early
but important data that HDM2 antagonism can effectively
restore p53 function, suppress melanoma growth, and
synergize with MEK inhibition. These results have direct
clinical implications and, in due time, may improve current
regimens involving selective MAPK pathway inhibitors.
MATERIALS AND METHODS
Reagents
Reagents were sourced as follows: U0126 from EMD chemicals
(Gibbstown, NJ), nutlin-3 and lentiviral-based shRNAs from Sigma-
Aldrich (St Louis, MO), AZD6244 from Selleck Chemicals (Houston,
TX), pERK, p53, p21, and GAPDH antibodies from Cell Signaling
Technology (Beverly, MA), p53-luciferase vector from Add-
gene (Cambridge, MA), and the Caspase-Glo 3/7 assay kit from
Promega (Fitchburg, WI).
Cell culture
Details of melanoma cell lines have been previously published (Tsao
et al., 2004; Yang et al., 2005; McDermott et al., 2007). The lines
were cultured in DMEM supplemented with 10% fetal bovine serum
in humidified atmosphere of 5% CO2/95% air at 37 1C to
confluence. The medium was replaced every 2–3 days.
Drug treatment and cell viability assay
Cell growth was determined by the AlamarBlue (Molecular Probes/
Invitrogen, Carlsbad, CA) fluorescence assay. Cells were seeded at a
density of 3,000 cells (100 ml) per well in a 96-well plateB12 hours
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Figure 5. p53 is required for nutlin-mediated apoptosis. A375 cells were
infected with small hairpin RNA against p53 and a stable knockdown line was
generated (A375sh-p53). (a) A375sh-p53 cells show blunted p53 deployment and
HDM2 and p21 induction compared with A375sh-GFP controls. (b) The
induction of apoptosis by various drug combinations was essentially
abrogated in the absence of p53. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; GFP, green fluorescent protein.
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before drug exposure. The plates were incubated with drugs for
48 hours. A volume of 10 ml of AlamarBlue was added to each well
and incubated for 3 hours at 37 1C. AlamarBlue is a fluorescent
substrate reduced by mitochondrial enzyme activity in viable cells.
Fluorescence intensity was determined using a Molecular Devices
plate reader (Molecular Devices, Sunnyvale, CA) with an excitation
filter centered at 540 nm and an emission filter centered at 590 nm.
Molecular analyses
DNA was purified from the cell lines using a DNEasy Kit (Qiagen,
Valencia, CA). TP53 (exons 4–10) sequencing was performed by
Sanger sequencing through a commercial site (Polymorphic DNA
Technologies, Alameda, CA). BRAF sequencing was performed by
Sanger sequencing using primers published in Davies et al., 2002.
DNA samples from the cell lines were also sent to the MGH genetics
core (Partners HealthCare, Center for Personalized Genetic Medi-
cine, Cambridge, MA) and subjected to single-nucleotide poly-
morphism/comparative genomic hybridization with the Affymetrix
GeneChip Human Mapping 250K Array (Affymetrix, Santa Clara,
CA). CDKN2A CN was analyzed using chromosome 9p21 probes
from the microarray. Data analysis was performed using Nexus 5.1
software (BioDiscovery, El Segundo, CA).
Stable shRNA infection
Lentiviral shRNA supernatant was produced by transient transfection
of HEK293T cells (ATCC, Manassas, Va) using Lipofectamine
(Invitrogen Life Technologies, Carlsbad, CA), according to the
manufacturer’s instructions. Plasmids used were the short hairpin
RNAs in pLKO.1-puro vector (Sigma-Aldrich) or pMKO.1-puro
vector (Addgene). The virus-containing supernatants were harvested
48 hours after transfection and were filtered through a 0.45-mm filter
unit. To transduce melanoma cells with lentivirus shRNAs,
logarithmically growing melanoma cells were seeded at a density
of 2 105 cells per well in six-well plates. A volume of 0.5ml of
lentivirus suspension and 8mgml1 of polybrene were added to
DMEM along with 5% fetal bovine serum in a total volume of 1ml.
Cells were allowed to incubate at 37 1C for 12 hours before removing
the medium and replacing with 2ml of fresh DMEM for expansions
of the transductants. At 24 hours after lentiviral infection, cells were
selected with puromycin at 1.5 mmol l1 for another 5 days before
further experiments.
Caspase 3/7 activity assay
Melanoma cells were grown in 96-well plates and treated with
inhibitors for 48hours. The Caspase-Glo 3/7 Reagent was then added
to each well and incubated for 30minutes. Caspase 3/7 activity was
detected using the Caspase-Glo 3/7 Assay system (Promega #G8091)
and performed as per the manufacturer’s protocol.
Cell cycle analysis
Cell cycle stage was determined using flow cytometry. Briefly,
treated melanoma cells were fixed with 70% ethanol at 20 1C for
1 hour. The cells were resuspended in 1ml of phosphate-buffered
saline containing propidium iodide (5 mgml1) and RNase A
(0.1mgml1) and were incubated at 37 1C for 30minutes. The
cells (104 cells per analysis) were examined by flow cytometry
(Beckman Coulter, Indianapolis, IN), and the cell cycle distribution
was determined by DNA content. Cells distributed in sub-G1 were
defined as apoptotic according to the criteria described by others
(Oancea et al., 2006).
Immunoblotting analysis
Equal amounts of protein (5–30 mg) were loaded onto 10% SDS
polyacrylamide mini-gels (Bio-Rad, Hercules, CA) and transferred to
polyvinylidene difluoride membranes. After being blocked in 5%
milk in TBS-Tween for 1 hour, blots were incubated with primary
antibodies overnight, followed by application of horseradish
peroxidase-conjugated secondary antibody (1:5,000) for 45minutes.
Antigen–antibody complexes were detected by enhanced chemi-
luminescence.
Combination indices
The CI was calculated using the software CompuSyn (http://
www.combosyn.com) based on the methodology of Chou (2010).
CIs were classified as Very Strong Synergism (CIo0.1), Strong
Synergism (CI¼ 0.1–0.3), Synergism (CI¼ 0.3–0.7), Moderate Syner-
gism (CI¼ 0.7–0.85), Slight Synergism (CI¼ 0.85–0.9), Nearly
Additive (CI¼ 0.9–1.10), and Antagonism (CI 41.0).
Statistics
Differences between the mean fractional survivals were statistically
assessed with the Student’s t-test for normally distributed samples and
the Mann–Whitney test for nonparametric comparisons. All analyses
were performed using SigmaStat (Systat Software, San Jose, CA).
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